Standout Papers
- The molecular classification of multiple myeloma (2006)
- Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial (2016)
Immediate Impact
3 by Nobel laureates 9 from Science/Nature 64 standout
Citing Papers
Transient loss of Polycomb components induces an epigenetic cancer fate
2024 StandoutNature
Diagnosis and Management of Multiple Myeloma
2022 Standout
Works of Joshua Epstein being referenced
Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT)
2020
Seven-year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic disease
2008
Author Peers
| Author | Last Decade | Papers | Cites | |||
|---|---|---|---|---|---|---|
| Joshua Epstein | 8336 | 7140 | 5120 | 274 | 12.4k | |
| Sonja Zweegman | 6260 | 4991 | 4479 | 326 | 10.1k | |
| Seema Singhal | 6934 | 4501 | 3910 | 284 | 10.5k | |
| Jeffrey R. Sawyer | 4197 | 4853 | 2078 | 275 | 9.7k | |
| Kevin Shannon | 3699 | 6088 | 2200 | 274 | 12.3k | |
| William Krivit | 4138 | 3589 | 1678 | 279 | 14.4k | |
| Ömer Yılmaz | 2404 | 4446 | 2192 | 400 | 12.8k | |
| Roland Mertelsmann | 3572 | 3365 | 4673 | 246 | 12.0k | |
| Jane L. Liesveld | 3644 | 2729 | 2254 | 247 | 8.0k | |
| Nelson J. Chao | 5307 | 2017 | 2720 | 336 | 10.8k | |
| R.J. Arceci | 2994 | 5071 | 3514 | 389 | 12.3k |
All Works
Login with ORCID to disown or claim papers
Loading papers...